Cargando…

Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness

BACKGROUND: GLP1R agonists provide multiple benefits to patients with type 2 diabetes – including improved glycemic control, weight loss, and decreased risk of major adverse cardiovascular events. Because drug responses vary among individuals, we initiated investigations to identify genetic variants...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Simeon I., Montasser, May E., Yuen, Ashley H., Fan, Hubert, Yazdi, Zhinoosossadat Shahidzadeh, Whitlatch, Hilary B., Mitchell, Braxton D., Shuldiner, Alan R., Muniyappa, Ranganath, Streeten, Elizabeth A., Beitelshees, Amber L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055582/ https://www.ncbi.nlm.nih.gov/pubmed/36993363 http://dx.doi.org/10.1101/2023.03.15.23287166

Ejemplares similares

Acute pharmacodynamic responses to sitagliptin: Drug-induced increase in early insulin secretion in oral glucose tolerance test
por: Beitelshees, Amber L., et al.
Publicado: (2023)

THU397 Homeostatic Regulation Of 1,25-dihydroxyvitamin D: Critical Role Of 24-hydroxylation (CYP24A1)
por: Yazdi, Zhinoosossadat Shahidzadeh, et al.
Publicado: (2023)

Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker
por: Taylor, Simeon I., et al.
Publicado: (2023)

Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse effects on 1,25-dihydroxyvitamin D and PTH
por: Yazdi, Zhinous Shahidzadeh, et al.
Publicado: (2023)

Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study
por: Acosta, Andres, et al.
Publicado: (2015)

Clinical impact of recent genetic discoveries in osteoporosis
por: Mitchell, Braxton D, et al.
Publicado: (2013)

When MINMOD Artifactually Interprets Strong Insulin Secretion as Weak Insulin Action
por: Ha, Joon, et al.
Publicado: (2021)

Effects of growth hormone administration on luteinizing hormone secretion in healthy older men and women
por: Muniyappa, Ranganath, et al.
Publicado: (2017)

THU269 Ethnic Differences In Hepatic Insulin Clearance: A Cross-Sectional Study Comparing South Asians And Non-Hispanic Whites
por: Ramanathan, Amrita L, et al.
Publicado: (2023)

Exenatide and Dapagliflozin Combination Enhances Sertoli Cell Secretion of Key Metabolites for Spermatogenesis
por: Ribeiro, João C., et al.
Publicado: (2022)

Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide
por: Pinkney, Jonathan, et al.
Publicado: (2010)

Effect of renal impairment on the pharmacokinetics of exenatide
por: Linnebjerg, Helle, et al.
Publicado: (2007)

Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
por: Beitelshees, Amber L., et al.
Publicado: (2019)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Endothelial Insulin and IGF-1 Receptors: When Yes Means NO
por: Muniyappa, Ranganath, et al.
Publicado: (2012)

Glycogen Synthase Kinase-3β and Cathepsin B in Diabetic Endothelial Progenitor Cell Dysfunction: An Old Player Finds a New Partner
por: Muniyappa, Ranganath, et al.
Publicado: (2014)

Dicarbonyl Stress and Atherosclerosis: Is It All RAGE?
por: Muniyappa, Ranganath, et al.
Publicado: (2014)

Minimal Model–Derived Insulin Sensitivity Index Underestimates Insulin Sensitivity in Black Americans
por: Fosam, Andin, et al.
Publicado: (2021)

KCNQ1 and Long QT Syndrome in 1/45 Amish: The Road From Identification to Implementation of Culturally Appropriate Precision Medicine
por: Streeten, Elizabeth A., et al.
Publicado: (2020)

Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course
por: Bansal, Rashika, et al.
Publicado: (2020)

Long-acting preparations of exenatide
por: Cai, Yunpeng, et al.
Publicado: (2013)

MON-500 A Case of Tumor-Induced Osteomalacia Caused by Metastatic Prostate Cancer
por: Rahman, Wedad, et al.
Publicado: (2019)

SAT245 Hips Don’t Lie: A Case Of Peri-Prosthetic Pseudotumor Leading To Hypercalcemia After Total Hip Replacement.
por: Sotomayor, Fiorella, et al.
Publicado: (2023)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

An Amish founder population reveals rare-population genetic determinants of the human lipidome
por: Montasser, May E., et al.
Publicado: (2022)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

MON-327 A Case of Parathyroid Carcinoma in a Patient with Late Stage Chronic Kidney Disease
por: Frunza-Stefan, Simona, et al.
Publicado: (2019)

PSUN253 Cocaine Use Resulting in Inadvertent Sulfonylurea Overdose
por: Gothong, Chikara, et al.
Publicado: (2022)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Exenatide: A New Promising Antidiabetic Agent
por: Chakraborti, C. K.
Publicado: (2010)

The use of exenatide in severely burned pediatric patients
por: Mecott, Gabriel A, et al.
Publicado: (2010)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Exenatide at mealtimes in type 1 diabetes—no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists
por: Doggrell, Sheila A.
Publicado: (2020)

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
por: Sarkar, Gayatri, et al.
Publicado: (2014)

Prevalence, control, and treatment of diabetes, hypertension, and high cholesterol in the Amish
por: He, Shisi, et al.
Publicado: (2020)

SAT-081 Advanced Lipoprotein Analysis Demonstrates Atherogenic Lipid Profile in Patients with Lipodystrophy That Improves after Metreleptin Treatment
por: Kinzer, Alexandra, et al.
Publicado: (2019)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
por: Simó, Rafael, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7lrt2n0k2b06uhs1hp2htseok2